MV130, a Sublingual Bacterial Immunotherapy to Prevent COPD Exacerbations - Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial

0 views
October 6, 2021
Comments 0
Login to view comments. Click here to Login